{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:26:31Z","timestamp":1793759191023,"version":"4.6.1"},"reference-count":25,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and efficacy of the dual GLP\u20101R\/GIPR agonist BGM0504 in Chinese adults with overweight or obesity without diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>\n                      In this randomized, double\u2010blind, placebo\u2010controlled, parallel\u2010group phase 2 trial, 120 participants were assigned (1:1:1:1) to receive once\u2010weekly subcutaneous injections of BGM0504 5\u2009mg, 10\u2009mg, 15\u2009mg, or placebo for 24\u2009weeks. The primary endpoint was percentage change in body weight from baseline to week 24. Key secondary endpoints included absolute body weight change, waist circumference, and the proportions of participants achieving prespecified weight\u2010loss targets. Safety was assessed using adverse events, laboratory tests, and vital signs. The trial was registered with the Chinese National Medical Products Administration (CTR20233198) and\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      (NCT06973681).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mean percentage changes in body weight from baseline to week 24 were \u221210.68%, \u221216.07%, \u221218.33%, and 0.13% with BGM0504 5\u2009mg, 10\u2009mg, 15\u2009mg, and placebo, respectively; all BGM0504 doses were significantly superior to placebo (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Mean reductions in waist circumference were \u22128.88\u2009cm, \u221212.71\u2009cm, \u221214.38\u2009cm, and \u22121.03\u2009cm, respectively (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001 vs. placebo). The proportions of participants achieving clinically meaningful weight loss increased in a dose\u2010dependent manner across BGM0504 groups versus placebo (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). PK analyses showed an approximately linear dose\u2010exposure relationship across the evaluated dose range. TEAEs occurred in 96.7%, 93.5%, 100.0%, and 86.7% of participants in the BGM0504 5\u2009mg, 10\u2009mg, 15\u2009mg, and placebo groups, respectively, and drug\u2010related adverse events occurred in 53.3%, 80.6%, 93.1%, and 40.0%. The most common selected TEAEs were gastrointestinal, including nausea, diarrhoea, and vomiting. One serious adverse event occurred in the 10\u2009mg group and no TEAEs led to trial withdrawal.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Once\u2010weekly BGM0504 was associated with substantial dose\u2010dependent weight loss and acceptable tolerability in Chinese adults with overweight or obesity without diabetes, supporting further clinical development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.71193","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:13:03Z","timestamp":1789708383000},"page":"11463-11474","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness, Safety and Pharmacokinetics of\n                    <scp>BGM0504<\/scp>\n                    , a Dual\n                    <scp>GLP<\/scp>\n                    \u20101\/\n                    <scp>GIP<\/scp>\n                    Receptor Agonist, in Chinese Adults With Overweight or Obesity Without Diabetes: A Phase 2 Multicentre, Randomized, Double\u2010Blind, Placebo\u2010Controlled Trial"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1305-1598","authenticated-orcid":false,"given":"Linong","family":"Ji","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism Peking University People's Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5930-586X","authenticated-orcid":false,"given":"Guoping","family":"Yang","sequence":"additional","affiliation":[{"name":"Center for Clinical Pharmacology The Third Xiangya Hospital, Central South University  Changsha China"},{"name":"Xiangya School of Pharmaceutical Sciences Central South University  Changsha China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangqing","family":"Huang","sequence":"additional","affiliation":[{"name":"BrightGene Bio\u2010Medical Technology Co. Ltd.  Suzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Ding","sequence":"additional","affiliation":[{"name":"BrightGene Bio\u2010Medical Technology Co. Ltd.  Suzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daosheng","family":"Xie","sequence":"additional","affiliation":[{"name":"BrightGene Bio\u2010Medical Technology Co. Ltd.  Suzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Jiang","sequence":"additional","affiliation":[{"name":"The Sweetwood Group LLC  Rockville Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Yuan","sequence":"additional","affiliation":[{"name":"BrightGene Bio\u2010Medical Technology Co. Ltd.  Suzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Cao","sequence":"additional","affiliation":[{"name":"Beijing Noahpharm Medical Technology Co. Ltd.  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zou","family":"Chan","sequence":"additional","affiliation":[{"name":"Center for Clinical Pharmacology The Third Xiangya Hospital, Central South University  Changsha China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Beijing Noahpharm Medical Technology Co. Ltd.  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiandong","family":"Yuan","sequence":"additional","affiliation":[{"name":"Center for Clinical Pharmacology The Third Xiangya Hospital, Central South University  Changsha China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"e_1_2_10_2_1","volume-title":"Obesity and Overweight","author":"World Health Organization","year":"2020"},{"issue":"25","key":"e_1_2_10_3_1","first-page":"S102","article-title":"2013 AHA\/ACC\/TOS Guideline for the Management of Overweight and Obesity in Adults","volume":"129","author":"Jensen M. D.","year":"2014","journal-title":"Circulation"},{"issue":"1","key":"e_1_2_10_4_1","first-page":"1","article-title":"The Importance of Weight Management in Type 2 Diabetes Mellitus","volume":"37","author":"Wilding J. P. H.","year":"2013","journal-title":"International Journal of Obesity"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta8210"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13690-024-01474-3"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0442"},{"key":"e_1_2_10_8_1","unstructured":"National Health Commission of the People's Republic of China \u201cReport on the Nutrition and Chronic Disease Status of Chinese Residents \u201d2020 https:\/\/english.scio.gov.cn\/pressroom\/2020\u201012\/23\/content_77043604.htm."},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310449"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102782"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2208601"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00213-0"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3224"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02026-4"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00008-0"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.23619"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01640-8"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12465"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1831"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"e_1_2_10_21_1","unstructured":"Lilly \u201cTreatment with Tirzepatide in Adults with Pre\u2010Diabetes and Obesity or Overweight Resulted in Sustained Weight Loss and Nearly 99% Remained Diabetes\u2010Free at 176\u2009Weeks \u201d2024 https:\/\/investor.lilly.com\/news\u2010releases\/news\u2010release\u2010details\/treatment\u2010tirzepatide\u2010adults\u2010pre\u2010diabetes\u2010and\u2010obesity\u2010or."},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-66998-8"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.9217"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/cob.12310"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20108587(23)00388\u20101"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2416394"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.71193","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.71193","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.71193","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:06:17Z","timestamp":1793757977000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/10.1111\/dom.71193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["10.1111\/dom.71193"],"URL":"https:\/\/doi.org\/10.1111\/dom.71193","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.71193\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71193\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71193\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71193\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71193\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71193\/v1\/review4","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71193\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71193\/v1\/decision1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"2026-04-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}